Definium Therapeutics Financials
This page shows Definium Therapeutics (DFTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Definium’s business model currently runs as a cash-consuming development platform, financed by repeated equity raises rather than operating revenue.
FY2025’s-$183.8M net loss was worse than its-$131.6M operating cash outflow, so reported earnings looked harsher than the company’s immediate cash drain. But fresh financing of$267.3M arrived as R&D spending climbed to$117.7M , showing the business is using outside capital to expand development activity rather than to harvest operating cash.
With
Long-term debt was just
Financial Health Signals
Definium Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Definium Therapeutics passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Definium Therapeutics reported a net loss of $183.8M while operations used $131.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Definium Therapeutics reported an operating loss of $166.3M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Definium Therapeutics reported -$183.8M in net income in fiscal year 2025. This represents a decrease of 69.1% from the prior year.
Definium Therapeutics earned -$2.06 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Definium Therapeutics held $257.8M in cash against $40.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Definium Therapeutics's ROE was -55.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Definium Therapeutics invested $117.7M in research and development in fiscal year 2025. This represents an increase of 80.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
DFTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $117.7M+80.2% | $65.3M+25.3% | $52.1M+44.1% | $36.2M+4.0% | $34.8M+86.7% | $18.6M |
| SG&A Expenses | N/A | $48.6M+26.0% | $38.6M-7.5% | $41.7M+38.4% | $30.2M-48.9% | $59.1M+310.2% | $14.4M |
| Operating Income | N/A | -$166.3M-60.0% | -$103.9M-10.7% | -$93.9M-41.5% | -$66.3M+29.3% | -$93.9M-184.1% | -$33.0M |
| Interest Expense | N/A | $5.5M+140.1% | $2.3M+148.2% | $920K-38.5% | $1.5M+516.4% | -$359K-118.9% | -$164K |
| Income Tax | N/A | $0 | N/A | N/A | N/A | -$1.2M | N/A |
| Net Income | N/A | -$183.8M-69.1% | -$108.7M-13.5% | -$95.7M-68.6% | -$56.8M+39.0% | -$93.0M-174.1% | -$33.9M |
| EPS (Diluted) | — | -$2.06-33.8% | -$1.54 | -$2.44-32.6% | -$1.84+45.9% | -$3.40 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DFTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $440.1M+45.7% | $302.2M+142.6% | $124.5M-26.7% | $170.0M+3.7% | $164.0M+101.2% | $81.5M |
| Current Assets | $419.3M+48.9% | $281.6M+171.1% | $103.9M-28.9% | $146.1M+6.4% | $137.2M+68.3% | $81.5M |
| Cash & Equivalents | $257.8M-5.8% | $273.7M+174.6% | $99.7M-29.9% | $142.1M+6.4% | $133.5M+66.7% | $80.1M |
| Goodwill | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M | $0 |
| Total Liabilities | $107.8M+77.5% | $60.7M+30.8% | $46.4M+143.3% | $19.1M+54.6% | $12.3M+118.3% | $5.7M |
| Current Liabilities | $66.7M+71.7% | $38.8M+20.5% | $32.2M+80.2% | $17.9M+71.9% | $10.4M+246.0% | $3.0M |
| Long-Term Debt | $40.6M+85.7% | $21.9M+54.7% | $14.1M | N/A | N/A | N/A |
| Total Equity | $332.3M+37.6% | $241.4M+209.0% | $78.1M-48.2% | $150.9M-0.5% | $151.7M+99.9% | $75.9M |
| Retained Earnings | -$582.7M-46.1% | -$398.9M-37.4% | -$290.2M-49.2% | -$194.5M-41.3% | -$137.7M-208.4% | -$44.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
DFTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$168.0M | -$131.6M-66.3% | -$79.1M-22.9% | -$64.4M-28.4% | -$50.1M-9.4% | -$45.8M-94.2% | -$23.6M |
| Investing Cash Flow | -$224.3M | -$151.6M | $0 | N/A | N/A | -$297K | N/A |
| Financing Cash Flow | $1.0B | $267.3M+5.6% | $253.2M+1058.9% | $21.8M-63.0% | $59.1M-40.2% | $98.8M+2.2% | $96.7M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DFTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -55.3%-10.3pp | -45.0%+77.5pp | -122.5%-84.9pp | -37.6%+23.7pp | -61.3%-16.6pp | -44.7% |
| Return on Assets | -41.8%-5.8pp | -36.0%+40.9pp | -76.9%-43.5pp | -33.4%+23.3pp | -56.7%-15.1pp | -41.6% |
| Current Ratio | 6.29-1.0x | 7.25+4.0x | 3.22-4.9x | 8.16-5.0x | 13.18-13.9x | 27.10 |
| Debt-to-Equity | 0.120.0x | 0.09-0.1x | 0.18+0.1x | 0.130.0x | 0.080.0x | 0.07 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Where Definium Therapeutics Ranks
Frequently Asked Questions
Is Definium Therapeutics profitable?
No, Definium Therapeutics (DFTX) reported a net income of -$183.8M in fiscal year 2025.
How much debt does Definium Therapeutics have?
As of fiscal year 2025, Definium Therapeutics (DFTX) had $257.8M in cash and equivalents against $40.6M in long-term debt.
What is Definium Therapeutics's return on equity (ROE)?
Definium Therapeutics (DFTX) has a return on equity of -55.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Definium Therapeutics's operating cash flow?
Definium Therapeutics (DFTX) recorded an outflow of $131.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Definium Therapeutics's total assets?
Definium Therapeutics (DFTX) had $440.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Definium Therapeutics spend on research and development?
Definium Therapeutics (DFTX) invested $117.7M in research and development during fiscal year 2025.
What is Definium Therapeutics's current ratio?
Definium Therapeutics (DFTX) had a current ratio of 6.29 as of fiscal year 2025, which is generally considered healthy.
What is Definium Therapeutics's debt-to-equity ratio?
Definium Therapeutics (DFTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Definium Therapeutics's return on assets (ROA)?
Definium Therapeutics (DFTX) had a return on assets of -41.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Definium Therapeutics's cash runway?
Based on fiscal year 2025 data, Definium Therapeutics (DFTX) had $257.8M in cash against an annual operating cash burn of $131.6M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Definium Therapeutics's Piotroski F-Score?
Definium Therapeutics (DFTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Definium Therapeutics's earnings high quality?
Definium Therapeutics (DFTX) reported a net loss of $183.8M while operations used $131.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Definium Therapeutics cover its interest payments?
Definium Therapeutics (DFTX) reported an operating loss of $166.3M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.